Phase 2 Oesophageal Cancer Trial, Recruiting NCT04278287 Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 2 Oesophageal Cancer Trial, Recruiting

NCT04278287
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 75 years
  • People who have been diagnosed with a type of oesophageal (food pipe) cancer called squamous cell carcinoma that cannot be removed by surgery, confirmed through a tissue or cell sample, and at a specific stage of spread as assessed by the trial team
  • People whose cancer spread is limited only to nearby lymph nodes near the collarbone or abdomen (confirm with trial site)
  • People who are receiving their primary cancer treatment at the Cancer Hospital, Chinese Academy of Medical Sciences
  • People who are generally active and able to care for themselves, with a good performance level as rated by a doctor
  • People whose nutritional status is assessed as adequate using a standard screening tool (confirm with trial site)
  • People whose estimated life expectancy is at least 3 months
  • People whose blood, kidney, and liver test results fall within acceptable ranges as determined by the trial team
  • People who have given their written agreement to take part in the trial

Who may not be able to join:

  • People whose cancer has spread to distant parts of the body such as the liver, lungs, bones, or brain, or to lymph nodes outside the specific regions defined by the trial
  • People who have had another type of cancer in the past 5 years, except for certain early-stage or non-aggressive skin cancers as specified by the trial team
  • People who currently have an active infection, such as active tuberculosis or hepatitis
  • People who have had a heart attack in the past 6 months, or who have a history of certain irregular heart rhythms
  • People with serious uncontrolled health conditions, including active infection, heart failure, unstable chest pain, heart rhythm problems, or serious mental health conditions
  • People who have had an allergic reaction to paclitaxel, albumin, or cisplatin (the medicines used in this trial)
  • People who are currently taking part in another clinical trial, or who have done so within the 4 weeks before joining this trial
  • People who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Xin Wang, MD, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Phone: +861013311583220

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Registry
ClinicalTrials.gov
Start date
1 October 2019
Est. completion
1 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Local control rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov